NAD⁺
CAS 53-84-9
Purity≥99.0%
NAD coenzyme material for biochemical and assay development
NAD+ (oxidized β-nicotinamide adenine dinucleotide, CAS 53-84-9) is supplied as a ≥99.0% coenzyme powder for enzyme and biochemical development. NADH is a separate reduced cofactor. PathGene provides lot-matched COA and evaluation samples; MOQ 1 kg, with 1 kg, 5 kg and 25 kg packs. NAD+ ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | NAD coenzyme material for biochemical and assay development |
| Application Scenarios | coenzyme assay development · enzyme-reaction systems · biochemical reference material |
| CAS Number | 53-84-9 |
| Purity | ≥99.0% |
| Molecular Formula | C₂₁H₂₇N₇O₁₄P₂ |
| Molecular Weight | 663.43 g/mol |
| Appearance | White to off-white powder |
| Solubility | Soluble in water |
| Storage | Sealed packaging, stored at cool, dry and away from light |
| Shelf Life | 18 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
β-Nicotinamide Adenine Dinucleotide (NAD⁺, CAS 53-84-9, C21H27N7O14P2, MW 663.43 g/mol) is a dinucleotide coenzyme formed by an adenine nucleotide and a nicotinamide nucleotide joined through a pyrophosphate bridge. It occurs naturally in every living cell, where it serves as the principal redox carrier in glycolysis, the TCA cycle, oxidative phosphorylation, and as a substrate for sirtuins and other NAD-consuming enzymes; it was first isolated from yeast extract in the early 1900s. Because chemical total synthesis of NAD⁺ is structurally complex and cost-prohibitive at scale, commercial bulk material is typically produced through microbial fermentation or biosynthetic/enzymatic routes using engineered yeast or bacterial strains that accumulate high intracellular NAD⁺ pools, followed by cell lysis, extraction, and chromatographic purification to the required purity grade.
Low-Endotoxin Batch Test Data
The tested NAD+ batch recorded endotoxin ≤0.1 EU/mg in third-party testing. Request the corresponding report for project evaluation.
Lyophilized, Water-Soluble Powder
Supplied as lyophilized powder produced in a GMP workshop and designed for aqueous reconstitution. Confirm clarity, pH compatibility and stability in the final matrix.
High Assayed Purity
Each batch is assayed at ≥98.0% purity by HPLC, meeting the requirements commonly expected for dietary supplement and biochemical research applications.
Controlled Biosynthetic Production
Produced on a synthetic biology and enzymatic-conversion platform with engineered production strains and closely monitored fermentation parameters, supporting consistent batch-to-batch quality.
Consistent Powder Form
Supplied as a white to off-white powder with controlled particle size, facilitating accurate weighing, blending, and downstream formulation.
Comprehensive Contaminant Screening
Every batch is screened for heavy metals (Pb, Hg, Cd, As) and microbial limits (total plate count, yeast/mold, E. coli, Salmonella) under an ISO9001-based quality system.
Flexible Bulk & OEM Supply
Available in flexible bulk quantities with OEM/private-label packaging options to support brand owners, formulators, and distributors of varying order sizes.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PG01-260423
Test date
2026-04-24
Specification
In-house
Pack size
25 kg/carton
Storage
Sealed packaging, stored at cool, dry and away from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to off-white crystalline powder | Complies |
| Identification | HPLC main peak retention time consistent with reference | Complies |
| Purity | ≥99.0% | 99.6% |
| Assay (dry basis) | ≥98.0% | 98.6% |
| Loss on drying | ≤8% | 7.2% |
| pH | 2.0–4.0 | 3.3 |
| Ethanol residue | ≤1% | ≤0.01% |
| Lead (Pb) | ≤0.1 ppm | Complies |
| Mercury (Hg) | ≤0.1 ppm | Complies |
| Cadmium (Cd) | ≤0.2 ppm | Complies |
| Arsenic (As) | ≤0.1 ppm | Complies |
| Total microbial count | ≤500 CFU/g | <10 |
| Coliform | ≤0.92 MPN/g | Complies |
| Mold and yeast | ≤50 CFU/g | Complies |
| Staphylococcus aureus | 0/25 g | Complies |
| Salmonella | 0/25 g | Complies |
| Bulk density | — | 0.72 g/ml |
| Tapped density | — | 0.87 g/ml |
| Particle size | NLT 95% pass 60 mesh | Conforms |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Dietary supplements
Enzyme catalysis
Pharmaceutical and API development
Diagnostic reagent raw materials
Oxidized NAD⁺ and NADH are not interchangeable; biocatalysis, assays and oral development need separate quality criteria.
99.6%
Purity
98.6%
Assay (dry basis)
PG01-260423 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
Oxidized NAD⁺ supports enzyme and analytical development; separate the standard, extraction and readout requirements of each redox form.
Show research and formulation insights +Hide details −Combination / selection rationale: Oxidized NAD⁺ supports enzyme and analytical development; separate the standard, extraction and readout requirements of each redox form.
Published evidence / source details: A 2022 study established luminescent microplate assays for ATP and NAD(H) in marine bacteria, evaluating plate crosstalk, extraction and incubation. NAD⁺ and NADH were characterized separately.
Development insights: Prepare NAD⁺ calibration levels with NADH cross-controls and compare buffer and matrix recovery. Validate extraction conversion, timing and lot effects; HPLC purity alone is not a quantitative mass-content standard.
Evidence scope: A bacterial-sample method precedent, not universal human diagnostic performance or certified-reference-material status.
2022 · Luciferase-based ATP/NAD(H) determination · DOI 10.1159/000522414 ↗NAD⁺ and PQQ are distinct ingredients for redox/mitochondrial research concepts, requiring separate assay and stability control.
Show research and formulation insights +Hide details −Combination / selection rationale: NAD⁺ and PQQ are distinct ingredients for redox/mitochondrial research concepts, requiring separate assay and stability control.
Published evidence / source details: A 2017 PQQ study examined SIRT1/PGC-1α and mitochondrial markers in mouse fibroblasts, without testing this exact exogenous-NAD⁺ blend.
Development insights: Premix low-level PQQ before staged NAD⁺ blending; assay both ingredients and evaluate colour, moisture and fill uniformity. Liquids need separate pH, addition-order and packaged-retention tests.
Evidence scope: Mechanism-informed candidate, without human-synergy inference from intracellular NAD⁺ changes.
2017 · PQQ SIRT1/PGC-1α study · DOI 10.1021/acs.biochem.7b01185 ↗The ingredients differ in aqueous behaviour and research role, suggesting comparisons of dry blends and separate formats.
Show research and formulation insights +Hide details −Combination / selection rationale: The ingredients differ in aqueous behaviour and research role, suggesting comparisons of dry blends and separate formats.
Published evidence / source details: A 2016 review discusses NAD⁺ metabolism and sirtuin-activating compounds including resveratrol, rather than a randomized trial of this exact finished blend.
Development insights: Set separate loading targets and test uniformity, disintegration and retention. Aqueous systems require resveratrol dispersion/settling and NAD⁺ assay, distinguishing suspension from dissolution.
Evidence scope: A retained development concept; NMN/resveratrol evidence is not interchangeable with NAD⁺ evidence.
2016 · NAD⁺ / sirtuin-activator review · DOI 10.1038/nrm.2016.93 ↗TMG and NAD⁺ address methyl-donor and coenzyme systems as independently selected development modules.
Show research and formulation insights +Hide details −Combination / selection rationale: TMG and NAD⁺ address methyl-donor and coenzyme systems as independently selected development modules.
Published evidence / source details: A 2005 review describes betaine-dependent homocysteine remethylation via BHMT, without validating synergy of a NAD⁺/TMG product.
Development insights: Specify identity and assay basis separately and compare size, density and moisture uptake before premixing. Assay each active and serving uniformity with single-ingredient, blend and carrier controls.
Evidence scope: A biochemically informed candidate, not a requirement for additional TMG.
2005 · Betaine / one-carbon metabolism · DOI 10.1515/CCLM.2005.187 ↗Literature-Supported Research Directions
NAD⁺/NADH are central redox coenzymes in glycolysis, the TCA cycle and oxidative phosphorylation. Research focuses on their dynamics in cellular energy metabolism and redox homeostasis.
Citation: Yang et al. NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy. Biochimica et biophysica acta (2016). PMID: 27374990.View source
NAD⁺ also serves as a substrate for sirtuins, PARPs and CD38, linking protein deacetylation, DNA-damage responses, inflammatory signaling and NAD⁺ homeostasis.
Citation: Covarrubias et al., Nature Reviews Molecular Cell Biology (2021): NAD⁺ metabolism and cellular processes during ageing.View source
Current work examines how NAD⁺ synthesis, consumption and compartmentalization influence metabolism, DNA repair, mitochondrial homeostasis and stress responses, primarily in biochemical and cellular models.
Citation: Xie et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal transduction and targeted therapy (2020). PMID: 33028824.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Strain Selection & Seed Culture
A high-yield production strain (engineered yeast or bacterium), optimized through synthetic biology approaches for elevated intracellular NAD⁺ accumulation, is activated and expanded through seed culture stages.
Controlled Fermentation
The seed culture is transferred to production bioreactors where temperature, pH, dissolved oxygen, and nutrient feeding are closely controlled to maximize intracellular NAD⁺ titer.
Cell Harvest & Disruption
Fermentation broth is harvested by centrifugation or filtration, and the cell biomass is disrupted (mechanically or enzymatically) to release intracellular NAD⁺ into solution.
Extraction
The lysate undergoes aqueous extraction under controlled thermal and pH conditions to solubilize NAD⁺ while minimizing degradation of the acid- and heat-sensitive nicotinamide-ribose bond.
Clarification & Impurity Removal
Cell debris, proteins, and nucleic acids are removed through precipitation, filtration, and decolorization steps to yield a clarified NAD⁺-containing solution.
Chromatographic Purification
Ion-exchange chromatography separates NAD⁺ from structurally related nucleotides and residual fermentation by-products to achieve the target purity level.
Concentration & Crystallization
The purified eluate is concentrated under vacuum and subjected to controlled crystallization or precipitation to isolate solid NAD⁺.
Drying, Milling & Packaging
The crystalline solid is dried under low-temperature or vacuum/freeze-drying conditions, milled and sieved to the specified particle size, then packaged under controlled humidity for shipment.
Purity is determined by high-performance liquid chromatography (HPLC) with UV detection, referencing a validated NAD⁺ standard and comparing retention time and peak area against related nucleotide impurities (e.g., NADH, AMP, nicotinamide). Buyers evaluating a supplier should confirm the specific HPLC method (column, mobile phase, detection wavelength), request the Certificate of Analysis (CoA) for the batch of interest, and, where regulatory submission is required, arrange independent third-party verification.
NAD⁺ is readily soluble in water and is supplied as a lyophilized powder for aqueous reconstitution. Evaluate pH, concentration, light exposure and hold time in the final matrix. A low-endotoxin result does not establish sterility, pyrogen-free status, injectable suitability or finished-product regulatory compliance.
No. This page supplies oxidized β-NAD, CAS 53-84-9. NADH is the reduced cofactor, and the separately listed NADH product is a disodium salt. Match the full chemical name, redox state and salt specification to the enzyme system or study method before comparing quotations or batch results.
No. The third-party endotoxin result of ≤0.1 EU/mg applies only to the tested batch. It does not by itself demonstrate sterility, pyrogen-free status, injectable suitability or finished-product regulatory compliance. The buyer must validate the final intended use.
Qualification of low-endotoxin NAD+ uses the supplied lot COA and a matching endotoxin report. Check the batch number, method, limit or result and test date. For a third-party report, also verify the laboratory and tested sample. Research and diagnostic-reagent projects should apply their own acceptance criteria.
It is supplied as lyophilized powder produced in a GMP workshop and is readily soluble in water. Reconstitution conditions, including concentration, pH, clarity and stability, should be confirmed in the target formulation.
The purity specification for NAD+ powder is ≥99.0%. Each batch is tested by HPLC, and its result is recorded in the matching COA. Review batch identity, test method and specification limits for acceptance.
The material is produced via a fermentation-based, biosynthetic/enzymatic process using an engineered production strain, followed by extraction and chromatographic purification, rather than through de novo chemical synthesis.
NAD⁺ is soluble in water and is commonly used in aqueous-based formats such as tablets, drops, and powder blends; formulation guidance can be discussed based on the intended finished product.
Yes, small samples are generally available for quality evaluation prior to a bulk purchase; please contact the sales team to arrange sample size and shipping terms.
Yes, buyers are welcome to submit samples to their own third-party laboratory for independent verification of purity, heavy metals, and microbial limits in addition to the CoA provided.
Yes, OEM and private-label options are available, including customized packaging, labeling, and formulation support for brand owners and finished-product manufacturers.
NAD+ powder pack options are 1 kg, 5 kg, 25 kg. Special inner-packaging, labeling and transport requirements are agreed separately for the order.
The raw-material MOQ for NAD+ powder is 1 kg, with pack options of 1 kg, 5 kg, 25 kg. Typical lead time is 3–5 business days, with dispatch confirmed for the order.
Specify oxidized NAD+, CAS 53-84-9, and distinguish it from NADH, NADP+ and NADPH. Match identity, appropriate assay basis and any redox-form impurities to the method. Use matrix recovery, blank and NADH cross-controls when developing quantitative assays; a raw-material COA does not establish certified-calibrant or diagnostic-kit performance.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Independent test record · Available by product/batch
Technical Resources
A procurement checklist for NAD+ bulk material covering identity, assay, related substances, elemental impurities, residual solvents, microbiology, and batch COA.
NMN, NAD+, NR, NRHM, NMNH, and NADH are often marketed as interchangeable "NAD+ precursors," but they differ in CAS identity, purity, salt form, and cost. This is a side-by-side decision guide for picking the right form for your formulation.
A procurement-focused guide to verifying a low-endotoxin NAD+ powder claim: lot-matched reports, test method, interference controls, packaging and the boundary between raw-material qualification and sterile-product release.
Related Products
NMN Powder (β-Nicotinamide Mononucleotide)
Nicotinamide Riboside Chloride Powder
Nicotinamide Riboside Hydrogen Malate Powder
Reduced Nicotinamide Mononucleotide (NMNH) Powder
Interested in NAD⁺?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
